US FDA panel backs Replimune skin cancer drug study data
- Posted on July 30, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
US FDA panel backs Replimune skin cancer drug study data
July 30 (Reuters) - A panel of outside advisers to the US Food and Drug Administration voted to back results from a trial studying Replimune's drug for a type of skin cancer in a meeting on Thursday. This comes after the FDA declined to approve the drug in April, citing reliance on a single-arm study without a control group, and sought more data from a well-controlled trial demonstrating adequate
